Medical / regulatory
Need
Target to define — Speed document reviews.
Remparia
Possible deployment — Pre-analysis pipeline + checklist, human sign-off.
// PROFESSIONS
Agents for pharma & life sciences
Documents, quality and scientific knowledge — under GxP, traceability and sovereignty.
// What guides our engagements
GxP
Regulated validation
SCOPE
Data inside the agreed frame
HITL
Human in the loop
Evidence
Outcomes defined before deployment
// The problem
Pains we know too well
Regulatory document volumes
Reviews and synthesis too slow for timelines.
Scattered scientific knowledge
Papers, SOPs, trials: signal hard to retrieve.
GxP / audit requirements
No opaque automation in a regulated environment.
// The solution
What Remparia can build for you
- Document assistants with audit trail
- Governed scientific / SOP RAG
- Quality / deviation agents with validation
- Audit-compatible architecture and governance
- Documentation, training and transfer of ownership to your teams
// Use cases
Three concrete use cases
Illustrative scenarios — every deployment is scoped with signed KPIs before production.
Quality
Need
Target to define — Better capitalize SOPs and deviations.
Remparia
Possible deployment — RAG + investigation assistant, full traceability.
Regulatory affairs
Need
Target to define — Consolidate regulatory watch without drowning teams in PDFs.
Remparia
Possible deployment — Watch agent on approved corpora: dated summaries, source links and major-change alerts.
// Related services
Missions that fit this industry
// FAQ
Frequently asked questions
GxP compatible?
We design with your validation / audit requirements — no shortcuts.
Clinical data?
Minimization, rights and hosting framed with your compliance teams.
Do we remain autonomous after deployment?
Yes. GxP SOPs, audit trails and e-signature rules are documented; regulatory validation stays internal.
// Other professions
Explore other professions
// READY TO START
Show us the workflow costing you time.
In one hour, we frame repetitive work, data constraints and the gains to measure — with a partner, not a salesperson.